A year into the COVID-19 pandemic, the use of RWE in clinical study design is becoming more widespread. In a recent informative dialogue, Dr. Nancy Dreyer of IQVIA spoke with Dr. Amy Abernethy of the FDA regarding the different types of data included under the RWE umbrella. Dr. Abernethy provides important insight into when and how RWE should be used.
“Seeking insights about FDA thinking on broadening the use of RWE? I had the privilege of talking with Dr. Amy Abernethy, FDA Principal Deputy Commissioner, and welcome you to listen in.” Learn more here.
(Source: IQVIA, 2/4/21)